Emmes, a world-class Clinical Research Organization (CRO) that’s dedicated to advancing public health and biopharmaceutical innovation, has taken a giant leap forward with the acquisition of Essex Management. Essex is a leading provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a crucial step for Emmes in its quest to provide clients with the best possible solutions and expand its services. By adding the expertise of Essex, Emmes will now be able to blaze new trails with government agencies and provide cutting-edge data strategies for biopharma clients.
The merger of Emmes and Essex will result in a clinical research powerhouse that’s at the forefront of data-driven solutions. With the combined might of Emmes’ advanced analytics solutions and Essex’s technology skills, the CRO will be better equipped to face global health challenges and shape the future of clinical research.
Essex’s reputation as a technology catalyst in the life sciences, combined with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will set the stage for a data-driven revolution in clinical research that will drive growth and bring new possibilities to life.
